Subscribe
type here...
Subscribe

Tag: RDIF

Clinical trials in Russia and Azerbaijan of the combination of AstraZeneca and Sputnik Light vaccines showed safety

Manufacturing Pharma -
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), R-Pharm group and AstraZeneca announce interim results of phase...

Vaccine against COVID Sputnik V granted full permanent approval in Russia

Global Markets Pharma -
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces that the Russian Sputnik V vaccine against coronavirus...

New investments in the innovative biotechnology company “Target Medicals”

Global Markets Pharma -
RDIF, AstraZeneca and Unicorn Capital Partners invest in Target Medicals, developing aldosterone synthase inhibitor for the treatment of resistant...

Spallanzani Institute in Italy: Sputnik V shows higher Omicron-antibody levels than Pfizer in preliminary study

Global Markets Pharma -
The Gamaleya National Research Center of Epidemiology and Microbiology (Gamaleya Center) and the Russian Direct Investment Fund (RDIF, Russia’s...

The combination of AstraZeneca and Sputnik Light vaccines in Azerbaijan shows strong neutralizing antibodies growth

Global Markets Pharma -
R-Pharm Group, the Russian Direct Investment Fund (RDIF) and AstraZeneca announce preliminary virus neutralizing activity results of combined use...

The single-component Sputnik Light vaccine authorized in Armenia

Manufacturing Pharma -
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) today announced the Russian single-component Sputnik Light vaccine against...

One shot Sputnik Light has high safety and 93.5% efficacy against COVID

Drug Development Pharma -
The heterogeneous boosting approach was at the core of Sputnik V, the world’s first registered vaccine against coronavirus.

Laboratorios Richmond delivers the first batch of over 1M doses of the Sputnik V produced in Argentina

Manufacturing Pharma -
Locally produced Sputnik V was supervised and verified by the National Administration of Drugs, Foods and Medical Devices of Argentina (ANMAT).

Combination of the Sputnik Light with others vaccines demonstrates high safety profile

Drug Development Pharma -
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.

Laboratorios Richmond to provide with over 3 million doses of the second component of the Sputnik V vaccine

Manufacturing Pharma -
RDIF and partners facilitated the technology transfer to Laboratorios Richmond for the local production of the vaccine with the first batch manufactured in April 2021.

Kazakhstan’s Karaganda pharmaceutical plant ready to manufacture Sputnik Light vaccine

Manufacturing Pharma -
By now, the Karaganda plant has manufactured five million doses of the Sputnik V vaccine.

The combination between the AstraZeneca vaccine and the Sputnik Light shows no serious adverse events

Drug Development Pharma -
In August 2021, RDIF and partners will publish initial data on the immunogenicity of the combined use of the AstraZeneca vaccine and the Sputnik V vaccine in Azerbaijan.

PHARMPROM is a premier digital resource for the pharmaceutical sector, combining breaking news, deep insights, and key market events. We cover the entire product lifecycle—from R&D and manufacturing to distribution—in strict accordance with Good Pharmaceutical Practices (GxP).

Disclaimer All content on pharmprom.net is for informational purposes only and does not constitute medical advice. The materials are intended exclusively for industry professionals and are not addressed to the general public.

Company

Headlines

Newsletter

Get important news delivered directly to your inbox and stay connected!

© PHARMPROM 2026